Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: Implications for stringent complete remission definition

Blood

Volumn 114, Issue 24, 2009, Pages 4954-4956

  De Larrea, Carlos Fernández ^a   Cibeira, María Teresa ^a   Elena, Montserrat ^a   Arostegui, Juan Ignacio ^a   Rosiñol, Laura ^a   Rovira, Montserrat ^a   Filella, Xavier ^a   Yagüe, Jordi ^a   Bladé, Joan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; OLIGOCLONAL BAND; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MULTIPLE MYELOMA; PREVALENCE; PRIORITY JOURNAL; REMISSION; TREATMENT RESPONSE; BLOOD; MIDDLE AGED; URINE;

ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OLIGOCLONAL BANDS; REMISSION INDUCTION;

EID: 73949088038     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-06-224832     Document Type: Article

References (18)

1. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by highdose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT: European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5):1115-1123.
2. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215-224.
3. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
4. Zent CS, Wilson CS, Tricot G, et al. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood. 1998;91(9):3518-3523.
5. Mark T, Jayabalan D, Coleman M, et al. Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br J Haematol. 2008;143(5):654-660.
6. Committee of the Chronic Leukemia-Myeloma Task Force. Proposed guidelines for protocol studies: II. Plasma cell myeloma. Prepared by a Committee of the Chronic Leukemia-Myeloma Task Force, National Cancer Institute. Cancer Chemother Rep. 1968;1(1):17-39.
7. Vickrey E, Allen S, Krishnamurthy J, Singh V, Mehta J, Singhal S. The utility of serum free light measurement in myeloma patients with oligoclonal bands on serum or urine immunofixation [abstract]. Blood. 2008;112(11): Abstract 5121.
8. Kumar S, Dispenzieri A, Larson D, et al. Normalization of the serum free light chain (FLC) ratio is associated with superior overall survival among myeloma patients achieving immunofixation negative state: results support incorporation of serum FLC ratio in stringent CR definition [abstract]. Blood. 2008;112(11): Abstract 1692.
9. Rosiñol L, Cibeira MT, Martínez J, et al. Thalidomide/dexamethasone vs Bortezomib (Velcade®)/thalidomide/dexamethasone (VTD) vs VBMCP/VBAD/Velcade® as induction regimens prior autologous stem cell transplantation (ASCT) in younger patients with multiple myeloma (MM) first results of a Prospective Phase III PETHEMA/Gem trial [abstract]. Blood. 2008;112(11): Abstract 654.
10. Cavo M, Tacchetti P, Patriarca F, et al. Superior complete response rate and progression-free survival after autologous transplantation with up-front Velcade-thalidome-dexamethasone compared with thalidomide-dexamethasone in newly multiple myeloma [abstract]. Blood. 2008;112(11):Abstract 158.
11. Harousseau JL, Mathiot C, Attal M, et al. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial [abstract]. J Clin Oncol. 2008;26[suppl 15]: Abstract 8505.
12. Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol. 2008;140(6):625-634.
13. Popat R, Oakervee HE, Hallam S, et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol. 2008;141(4):512-516.
14. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet. 2006;367(9513):825-831.
15. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594):1209-1218.
16. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917.
17. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol. 2007;25(28):4459-4465.
18. Lacy MQ, Gertz MA, Dispenzieri A, et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc. 2007;82(10):1179-1184.